01536nas a2200289   4500000000100000008004100001260000900042653001200051653002200063653003000085653001100115653001400126653002300140653001200163653001800175653001300193100001600206700001600222700001400238700001700252700002200269245005800291300001200349490000700361520086400368022001401232       1978                            d  c197810aDapsone10aDrug Combinations10aDrug Therapy, Combination10aHumans10aIsoniazid10aLeprostatic Agents10aleprosy10aProthionamide10aRifampin1 aFreerksen E1 aRosenfeld M1 aBonnici E1 aDepasquale G1 aKriiger-Thiemer M00aCombined therapy in leprosy. Background and findings.  a187-2010 v243 a<p>This report is based on data obtained from 64 lepromatous cases. Despite many years of DDS monotherapy, the homogenates from biopsies of these patients revealed 10(4) or more bacteria. From the beginning of combination therapy with synergistic-acting substances (rifampicin + isoprodian (INH + PTH + DDS) the logarithms of the number of bacteria in the homogenates decreased, both during treatment period and during treatment-free observation period (Figs. 3--8). During the whole time biopsies were taken almost monthly. A considerable regression of the bacterial mass or even "negativity" could be observed within a relatively short time. Once started, the process of reduction of bacteria continued also after termination of therapy. To be able to evaluate a medication, therapy-free observation periods (for a minimum of 5 years) are indispensable.</p>  a0009-3157